According to the weight document of the national stock index, as of April 30, the proportion of innovative drug weight in the innovative drug index (987018) of the CSI Hong Kong stock index has further increased to 90%.Capcomarcadestadiumps4The content of .14% cxo is further reduced to 9.52%. The purity of the innovative drug is higher, and the higher purity can lead to higher sharpness.Capcomarcadestadiumps4! The index tracked by Hong Kong Stock Tongchuang New Drug ETF (159570) continues to optimize, the purification of innovative drugs has been on the way, and the vitality of index self-renewal iteration is gradually reflected!
Today, Hong Kong stock Tongchuang new drug stocks soared again. Zaiding Pharmaceutical, which reported bright results in the first quarter, rose more than 15%, Baiji China, which also had excellent financial results, rose more than 6%, and Huang Pharmaceutical and Kangxino Biology rose more than 5%. China Biopharmaceuticals, Pharmaceutical Biology and Kanglongcheng have soared by more than 4%, with Tiger Pharmaceuticals and Pharmaceutical Kant among the top gainers.
Hong Kong stock Tongchuang new drug ETF (159570), which has the highest innovative drug content in the market, rose by more than 3.5% today, a new high in the continuous stage, and rebounded strongly by more than 20% since the low point of the stage, with outstanding characteristics of high purity and high elasticity! The total positions and corresponding weights of the Hong Kong Stock Exchange New Drug Index tracked by ETF (SZ159570) $are as follows:
Data source: national Securities Index Company, as of 2024.4.30
As can be seen from the above list of constituent stocks:
The top ten weights of Hong Kong stock Tongchuang new drug ETF (159570) together account for nearly 72%, with outstanding leading attributes.
According to the further subdivision of the constituent stocks, there are 27 innovative drugs, with a total weight of 90.14%, 6 cxo (pharmaceutical R & D outsourcing, etc.), 9.52% of the total weight, 1 vaccine, and 0.34% weight.
Overall, the innovative drug content of ETF (159570) is more than 90%, which is the highest in the pharmaceutical index of the whole market. as the purest innovative drug, ETF (159570) has attracted the attention of many investors because of its high sharpness and high elasticity.
Hong Kong Stock Exchange Innovation New Drug ETF (159570) has distinct characteristics:
Purer innovative drugs (up to 90% + weight ratio of innovative drugs, the highest in the pharmaceutical index in the market)
The most undervalued innovative drugs (the historical quantile of the latest price-to-sales ratio valuation is 6.98%)
The underlying assets are Hong Kong stocks, which can be traded with TFT 0.
Hong Kong stock through innovation new drug ETF (159570) closely tracks the national stock through innovation new drug index, which aims to reflect the operating characteristics of listed companies in Hong Kong stock through innovation new drug industry.
At present, the Hong Kong Stock and Innovation New Drug ETF connection Fund (Class A: 021030 X C: 021031) is in a hot release, providing you with a new weapon for the over-the-counter layout of the highest purity innovative drug products! All major online sales platforms can be subscribed!
Focus on the strength of China's hard-core innovative drugs, representatives of new quality productivity, identify Hong Kong stock innovative new drugs ETF (159570), over-the-counter connection (A: 021030 switch C: 021031).
Risk hint: the fund is risky, so you need to be cautious in investment. In this paper, individual stocks are only shown objectively as index stocks and do not represent any investment suggestions. Investors should read the legal documents such as the Fund contract to understand the risk-return characteristics of the fund. Hong Kong stock Tongchuang new drug ETF (159570) is a medium risk grade (R3) product, which is suitable for investors whose results are balanced (C3) or above after customer risk rating. The underlying index does not fully represent the entire stock market. The average rate of return of the underlying index stocks may deviate from that of the stock market as a whole. If the above products are invested in the overseas securities market, the net value of the fund will fluctuate due to the fluctuation of the securities market and other factors. The risk of overseas investment products includes market risk, exchange rate risk and so on. The information in this article is for reference only and the investor is responsible for any independent investment behavior. Any point of view, analysis and forecast in this article do not constitute any form of investment advice to the reader.